Home > Journals > La Rivista Italiana della Medicina di Laboratorio > Past Issues > Articles online first > La Rivista Italiana della Medicina di Laboratorio 2021 Sep 30

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

La Rivista Italiana della Medicina di Laboratorio 2021 Sep 30

DOI: 10.23736/S1825-859X.21.00114-6

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: Italian

Proteomic multiparametric assays to detect autoantibodies: a new paradigma for diagnosis, prevention, monitoring and personalized therapy in autoimmune diseases

Nicola BIZZARO 1, 2 , Luigi CINQUANTA 3

1 Laboratorio di Patologia Clinica, Ospedale San Antonio, Tolmezzo, Udine, Italia; 2 Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italia; 3 IRCCS S.D.N., Napoli, Italia


PDF


The recent development of multiparametric proteomic assay able to detect many autoantibodies in a single run might replace conventional immunoassays, allowing for a more efficient handling of large numbers of samples by the laboratory, while ensuring greater diagnostic sensitivity in the screening and better management of autoimmune diseases. In the near future, the introduction of multiparametric autoantibody proteomic technology will likely have a major impact on the diagnosis, monitoring, and therapy of autoimmune disease. Extended disease-specific autoantibody profiles consisting of dozens, if not hundreds of autoantibodies will be able to define each patient's autoantibody fingerprint and identify clinical phenotypes of patients with different prognostic characteristics and different therapeutic responses. In this review, we analyze the application and the potential of autoantibody profiles performed by proteomic multiplex immunoassays and the implications for personalized medicine.


KEY WORDS: Autoimmune diseases; Multiparametric assays; Personalized medicine; Microarray; Proteomic technology

top of page